IsoRay, Inc. (ISR)


NYSE MKT - NYSE MKT Real Time Price. Currency in USD
0.72+0.01 (+1.90%)
At close: 4:00 PM EDT
People also watch:
PBMDRNNMNGAIBIOAVEO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.73
Prev Close0.71
Bid0.66 x 1000
Ask0.90 x 3000
Day's Range0.70 - 0.74
52wk Range0.55 - 1.65
1y Target EstN/A
Market Cap39.61M
P/E Ratio (ttm)-8.37
Beta0.62
Volume46,181
Avg Vol (3m)87,907
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire3 days ago

    IsoRay, Inc. Announces Launch of Newly Redesigned Patient and Clinician Focused Corporate Website

    RICHLAND, Wash., Sept. 28, 2016 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the launch of its newly redesigned corporate website at www.isoray.com. The redesigned website introduces IsoRay's new branding and logo and offers quick and easy access to essential information that provides a comprehensive understanding of the Company's innovative Cesium-131 products. It is both patient and clinician focused and has an updated visual design and content structure which will make it easier for patients and medical teams to find what they're looking for.

  • PR Newswire4 days ago

    IsoRay, Inc. Enters Into Agreement to Settle Class Action Shareholder Litigation

    RICHLAND, Wash., Sept. 27, 2016 ­/PRNewswire/ -- IsoRay, Inc. ("IsoRay") (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck, and gynecological cancers, today announced that on September 23, 2016, it entered into a Stipulation of Settlement (the "Settlement"), pursuant to which IsoRay and IsoRay's former CEO (together, the "Defendants") have, subject to certain conditions and approvals, agreed to settle the previously-disclosed consolidated securities class action litigation, In re IsoRay, Inc. Securities Litigation, Case No. 4:15-cv-05046-LRS (the "Litigation"), pending in the U.S. District Court for the Eastern District of Washington. If the Settlement becomes final, among other things, (i) the claims against the Defendants will be dismissed with prejudice and released, such that every member of the settlement class will be barred from asserting against the Defendants any claims alleged in the complaint or arising from the complaint, and (ii) a payment of $3,537,500 will be made for the benefit of the settlement class, which IsoRay expects to be funded entirely by its insurance carriers.

  • Capital Cube7 days ago

    IsoRay, Inc. :ISR-US: Earnings Analysis: 2016 By the Numbers : September 23, 2016

    Categories: Yahoo Finance Get free summary analysis IsoRay, Inc. reports financial results for the year ended June 30, 2016. We analyze the earnings along side the following peers of IsoRay, Inc. – Accuray Incorporated, Hologic, Inc., STRATA Skin Sciences, Inc., C. R. Bard, Inc. and Varian Medical Systems, Inc. (ARAY-US, HOLX-US, SSKN-US, BCR-US and VAR-US) that have also ... Read more (Read more...)